Lithostat (acetohydroxamic acid), the only urease inhibitor available for urea-splitting urinary infections in association with struvite stones, is available again at pharmacies nationwide, according to the drug’s marketer, Mission Pharmacal.
Struvite stones make up about 15% of all kidney stones. Because struvite stones occur most commonly in those most susceptible to urinary tract infections, women develop them twice more than men.
In single clinical trials, the drug allowed successful antibiotic treatment of urea-splitting infections after surgical removal of struvite stones in patients not cured by three months of antibacterial treatment alone. It also reduced the rate of stone growth in patients who were not candidates for surgical removal of stones.
In a company press statement, Glenn Preminger, MD, Director of the Comprehensive Kidney Stone Center at Duke University Medical Center in Durham, N.C., noted: “For the people who suffer from struvite kidney stone disease, Lithostat can help them get back to a life not regulated by pain and discomfort. Considering the limited amount of treatments available for urea-splitting urinary infections and the resulting stones, this medication is an exciting option for patients and the physicians that treat them.”